Details of Disease

General Information of Disease (ID: DISIAZST)

Disease Name Undifferentiated carcinoma
Synonyms undifferentiated carcinoma; carcinoma, undifferentiated, malignant; carcinoma, undifferentiated; anaplastic carcinoma
Definition A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.
Disease Hierarchy
DISH9F1N: Carcinoma
DISIAZST: Undifferentiated carcinoma
Disease Identifiers
MONDO ID
MONDO_0005617
UMLS CUI
C0205698
MedGen ID
60010
SNOMED CT ID
38549000

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 80 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ABCB1 TT3OT40 Limited Biomarker [1]
ADCY5 TTN64VU Limited Biomarker [2]
AQP1 TTSF1KH Limited Biomarker [2]
ATP7B TTOPO51 Limited Biomarker [3]
BCL2L1 TTRE6AX Limited Biomarker [4]
CDK4 TT0PG8F Limited Biomarker [5]
CSF2 TTNYZG2 Limited Therapeutic [6]
ESR2 TTOM3J0 Limited Biomarker [7]
EZR TTE47YC Limited Biomarker [2]
FHIT TTMS54D Limited Biomarker [8]
FN1 TTPJ921 Limited Biomarker [2]
GDA TTK4JTZ Limited Biomarker [2]
GGT1 TTZVT7O Limited Biomarker [2]
GSS TTVEWR4 Limited Biomarker [2]
GSTP1 TT40K12 Limited Biomarker [9]
HIF1A TTSN6QU Limited Biomarker [10]
KRAS TTM8FR7 Limited Biomarker [11]
LPL TTOF3WZ Limited Biomarker [2]
MIF TT6804T Limited Biomarker [2]
MYC TTNQ5ZP Limited Biomarker [12]
PADI4 TTQHAXM Limited Altered Expression [13]
PEBP1 TT1BGU8 Limited Biomarker [2]
PGR TTUV8G9 Limited Biomarker [7]
PHB TT6U071 Limited Biomarker [2]
PLAUR TTNOSTX Limited Biomarker [14]
PLK2 TT976FS Limited Biomarker [2]
PPARA TTJ584C Limited Biomarker [15]
PTBP1 TTWMX0U Limited Biomarker [2]
RHOA TTP2U16 Limited Biomarker [16]
S1PR1 TT9JZCK Limited Biomarker [2]
SCARB1 TTRE324 Limited Biomarker [2]
STMN1 TT7W5OT Limited Biomarker [2]
TKT TT04R7I Limited Biomarker [2]
TSHR TT6NYJA Limited Biomarker [17]
TYMP TTO0IB8 Limited Biomarker [18]
VHL TTEMWSD Limited Biomarker [8]
XDH TT7RJY8 Limited Biomarker [2]
ACKR3 TTRQJTC Disputed Biomarker [19]
ACTG1 TTGAZF9 Disputed Biomarker [20]
ALCAM TT2AFT6 Disputed Biomarker [20]
ANXA1 TTUCK4B Disputed Biomarker [20]
EIF5A TTIVCNR Disputed Biomarker [20]
EPCAM TTZ8WH4 Disputed Biomarker [20]
FABP4 TTHWMFZ Disputed Biomarker [20]
FURIN TTH9WF6 Disputed Biomarker [20]
GATA3 TT45KOB Disputed Biomarker [20]
HNRNPA1 TTPJ9XK Disputed Biomarker [20]
KITLG TTDJ51N Disputed Biomarker [20]
LY96 TT8S9AV Disputed Biomarker [19]
MRC2 TTYVR8M Disputed Biomarker [20]
PDGFA TTSM78N Disputed Biomarker [20]
PKM TT4LOT8 Disputed Biomarker [20]
PTN TTA9EJK Disputed Biomarker [20]
RASA1 TTPNZ1F Disputed Biomarker [21]
RBP4 TT0C8BY Disputed Biomarker [20]
SNCG TT5TQNZ Disputed Biomarker [20]
TF TT8WXAV Disputed Biomarker [20]
TLR4 TTISGCA Disputed Biomarker [19]
UCP2 TTSC2YM Disputed Biomarker [20]
CLDN4 TTMTS9H moderate Altered Expression [22]
NCOA4 TT8OY02 moderate Biomarker [23]
PTEN TTXJ3W7 moderate Biomarker [24]
SMARCA4 TTVQEZS moderate Biomarker [25]
CDH1 TTLAWO6 Strong Biomarker [26]
CSF3 TT5TQ2W Strong Biomarker [27]
MET TTNDSF4 Strong Biomarker [28]
PTGS1 TT8NGED Strong Biomarker [29]
STAT3 TTHJT3X Strong Altered Expression [30]
TGFBR2 TTZE3P7 Strong Biomarker [31]
TIE1 TTT4236 Strong Biomarker [32]
ANGPTL4 TTWALY5 Definitive Biomarker [33]
CCND1 TTFCJ7S Definitive Biomarker [34]
DNMT1 TT6S2FE Definitive Biomarker [35]
DNMT3B TT6VZ78 Definitive Biomarker [35]
ESR1 TTZAYWL Definitive Biomarker [34]
MERTK TTO7LKR Definitive Biomarker [36]
PRLR TTBPXMA Definitive Biomarker [34]
S100A6 TT716MY Definitive Biomarker [20]
SCD TT6RIOV Definitive Biomarker [20]
SGK1 TTTV8EJ Definitive Biomarker [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 80 DTT(s)
This Disease Is Related to 2 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC12A2 DTHKL3Q Limited Biomarker [2]
SLC25A10 DTJYKDQ Limited Biomarker [2]
------------------------------------------------------------------------------------
This Disease Is Related to 3 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
EPHX1 DELB4KP Limited Biomarker [2]
GSTT1 DE3PKUG Strong Biomarker [37]
KYAT1 DES9MCU Strong Biomarker [37]
------------------------------------------------------------------------------------
This Disease Is Related to 87 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ACTN4 OTCNZAJ5 Limited Biomarker [2]
BASP1 OTF4VS5G Limited Biomarker [2]
BRCA1 OT5BN6VH Limited Biomarker [38]
CASK OT8EF7ZF Limited Biomarker [2]
CIRBP OTXWTPBL Limited Altered Expression [39]
CNN3 OTJTAXAP Limited Biomarker [2]
COL5A1 OT24078H Limited Biomarker [2]
COX1 OTG3O9BN Limited Biomarker [2]
DBI OT884QY9 Limited Biomarker [2]
DES OTI09KBW Limited Biomarker [2]
EEF1A1 OT00THXS Limited Biomarker [2]
EFEMP1 OTZVUOOB Limited Biomarker [2]
ENO1 OTB1KWJS Limited Biomarker [2]
GPLD1 OTUUQOVY Limited Altered Expression [30]
HBA1 OTW2BQF4 Limited Biomarker [2]
ID3 OTUULW5Z Limited Biomarker [2]
INSIG1 OTZF5X1D Limited Biomarker [2]
KRT5 OTVGI9HT Limited Biomarker [2]
LIN7A OTFL3PUX Limited Biomarker [2]
MDH2 OT7364GY Limited Biomarker [2]
NSMF OTLTA24A Limited Biomarker [2]
OXT OT48M72Z Limited Therapeutic [40]
RB1 OT9VMY7B Limited Biomarker [5]
RBP1 OTRP1MFC Limited Biomarker [2]
RPL6 OTRU71O4 Limited Biomarker [2]
TLE4 OT4QEH6T Limited Biomarker [2]
TP63 OT0WOOKQ Limited Biomarker [41]
ACSL1 OTB06ESI Disputed Biomarker [20]
ACTB OT1MCP2F Disputed Biomarker [20]
ANXA4 OTUCRYXL Disputed Biomarker [20]
CAPZB OTF1A4N0 Disputed Biomarker [20]
CCNH OTKDU3SR Disputed Biomarker [21]
CDC42 OT5QBC5M Disputed Biomarker [20]
CDS1 OT2F591M Disputed Biomarker [20]
CSN2 OT22C0PD Disputed Biomarker [20]
CSN3 OTR61MI8 Disputed Biomarker [20]
DUSP6 OT4H6RKW Disputed Biomarker [20]
G0S2 OT8FL49L Disputed Biomarker [20]
GATM OTIJ4Z11 Disputed Biomarker [20]
GNAI2 OTTLGRGH Disputed Biomarker [20]
ID4 OTPMJ39I Disputed Biomarker [42]
IL6ST OT1N9C70 Disputed Biomarker [21]
KRT71 OTI91X9Z Disputed Biomarker [20]
LGALS7 OTMSVI7R Disputed Biomarker [20]
MGP OTZWU3FU Disputed Biomarker [20]
MPZL1 OTJSUUHR Disputed Biomarker [20]
PGAM1 OTZ5DB06 Disputed Biomarker [20]
PIK3R1 OT5BZ1J9 Disputed Biomarker [21]
PRDX2 OTLWCY9T Disputed Biomarker [20]
PSMA4 OTAD2XXI Disputed Biomarker [20]
PSME1 OTDHLJWH Disputed Biomarker [20]
RAN OT2TER5M Disputed Biomarker [20]
RASGRF2 OT67DAGF Disputed Biomarker [21]
RCN1 OT3JBGAG Disputed Biomarker [20]
RPL3 OTX6VXLB Disputed Biomarker [20]
RPS14 OTB90KV5 Disputed Biomarker [20]
SOX9 OTVDJFGN Disputed Biomarker [20]
SPINT2 OTQV7BKQ Disputed Biomarker [20]
THRSP OTKYE01L Disputed Biomarker [20]
TPM3 OT5RU5G6 Disputed Biomarker [20]
TRPS1 OT7XPPEL Disputed Biomarker [20]
TSC22D1 OTN4GFWD Disputed Biomarker [20]
ADGRE2 OTUYJVYG moderate Altered Expression [43]
ADGRE5 OTTSB84Q moderate Altered Expression [43]
ARID1B OTILK3Q7 moderate Genetic Variation [44]
EMD OTR8ZANE moderate Altered Expression [45]
MAP1LC3A OTPMGIU4 moderate Altered Expression [46]
MRO OT5U38CP moderate Biomarker [47]
NUTM1 OTONYC08 moderate Altered Expression [48]
PPP2R1A OTYA3GB4 moderate Genetic Variation [49]
SMARCAL1 OTTKXLUZ moderate Genetic Variation [50]
ATP5IF1 OTQFD73H Strong Biomarker [20]
EMSY OTBQ3KQE Strong Biomarker [51]
H3-3B OT9XHQ3C Strong Biomarker [20]
IFNA17 OTHXRYG3 Strong Biomarker [52]
NUPR1 OT4FU8C0 Strong Biomarker [53]
HHEX OTLIUVYX Definitive Altered Expression [54]
LSR OTR8Y32X Definitive Biomarker [20]
NDN OTYBYJ82 Definitive Biomarker [33]
PDLIM7 OTAZVODU Definitive Genetic Variation [55]
SELENOP OT02B8IR Definitive Biomarker [20]
SMARCA1 OT0Y6PTU Definitive Biomarker [44]
SNRPD3 OTZXBQ45 Definitive Biomarker [20]
SRSF2 OTVDHO6U Definitive Biomarker [20]
STAT5A OTBSJGN3 Definitive Biomarker [34]
TMEM37 OT317PEL Definitive Biomarker [33]
TP53I3 OTSCM68G Definitive Biomarker [33]
------------------------------------------------------------------------------------
⏷ Show the Full List of 87 DOT(s)

References

1 Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer. Pharmacogenomics. 2011 Feb;12(2):205-14.
2 cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.Carcinogenesis. 2002 Oct;23(10):1561-8. doi: 10.1093/carcin/23.10.1561.
3 Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP.Int J Cancer. 2002 Oct 10;101(5):488-95. doi: 10.1002/ijc.10608.
4 Altered bcl-2 family expression during non-genotoxic hepatocarcinogenesis in mice.Carcinogenesis. 1999 Aug;20(8):1583-90. doi: 10.1093/carcin/20.8.1583.
5 Deregulation of the cyclin D1/Cdk4 retinoblastoma pathway in rat mammary gland carcinomas induced by the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.Cancer Res. 2003 Sep 15;63(18):5674-8.
6 Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A.Oncol Rep. 2001 Nov-Dec;8(6):1371-4.
7 Steroid hormone receptor expression and proliferation in rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.Carcinogenesis. 2005 Apr;26(4):763-9. doi: 10.1093/carcin/bgi013. Epub 2005 Jan 6.
8 Lung cancer susceptibility in Fhit-deficient mice is increased by Vhl haploinsufficiency.Cancer Res. 2005 Aug 1;65(15):6576-82. doi: 10.1158/0008-5472.CAN-05-1128.
9 Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1.Cancer Res. 2001 Jan 1;61(1):103-9.
10 Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas.Endocr Relat Cancer. 2010 Jan 29;17(1):61-72. doi: 10.1677/ERC-08-0251. Print 2010 Mar.
11 Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for targeted therapies.Hum Pathol. 2016 Mar;49:99-106. doi: 10.1016/j.humpath.2015.10.006. Epub 2015 Nov 2.
12 Oncogene expression of FANFT- or BBN-induced rat urothelial cells.Int J Cancer. 1990 Nov 15;46(5):913-8. doi: 10.1002/ijc.2910460527.
13 Investigating the pathogenic role of PADI4 in oesophageal cancer.Int J Biol Sci. 2011;7(6):769-81. doi: 10.7150/ijbs.7.769. Epub 2011 Jun 11.
14 DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.Exp Cell Res. 2004 Sep 10;299(1):91-100. doi: 10.1016/j.yexcr.2004.05.008.
15 Characterization of peroxisome proliferator-activated receptor alpha in normal rat mammary gland and 2-amino-l-methyl-6-phenylimidazo[4, 5-b]pyridine-induced mammary gland tumors from rats fed high and low fat diets.Toxicol Lett. 2000 Dec 20;118(1-2):79-86. doi: 10.1016/s0378-4274(00)00265-4.
16 Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma.Nat Genet. 2014 Jun;46(6):583-7. doi: 10.1038/ng.2984. Epub 2014 May 11.
17 Decreased expression of the thyroid-stimulating hormone receptor in poorly-differentiated carcinoma of the thyroid.Oncol Rep. 2008 Jun;19(6):1405-11.
18 Thymidine phosphorylase inhibits apoptosis induced by cisplatin.Biochem Biophys Res Commun. 2003 Feb 7;301(2):358-63. doi: 10.1016/s0006-291x(02)03034-6.
19 Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma.PLoS One. 2011;6(12):e27399. doi: 10.1371/journal.pone.0027399. Epub 2011 Dec 13.
20 Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.Toxicol Pathol. 2005;33(7):768-75. doi: 10.1080/01926230500437027.
21 Allelic imbalance and altered expression of genes in chromosome 2q11-2q16 from rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.Oncogene. 2003 Feb 27;22(8):1253-60. doi: 10.1038/sj.onc.1206233.
22 Frequent loss of claudin-4 expression in dedifferentiated and undifferentiated endometrial carcinomas.Histopathology. 2018 Aug;73(2):299-305. doi: 10.1111/his.13525. Epub 2018 May 31.
23 RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components.Histopathology. 2010 Sep;57(3):444-50. doi: 10.1111/j.1365-2559.2010.03646.x.
24 Undifferentiated and Dedifferentiated Endometrial Carcinomas With POLE Exonuclease Domain Mutations Have a Favorable Prognosis.Am J Surg Pathol. 2017 Aug;41(8):1121-1128. doi: 10.1097/PAS.0000000000000873.
25 SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas.J Thorac Oncol. 2020 Feb;15(2):231-247. doi: 10.1016/j.jtho.2019.10.023. Epub 2019 Nov 18.
26 Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma. Cancer. 2007 Jul 1;110(1):87-95. doi: 10.1002/cncr.22758.
27 Pseudomesotheliomatous carcinoma of the pleura: an autopsy case of metastasis from a G-CSF-producing anaplastic carcinoma of the pancreas.APMIS. 2018 Feb;126(2):166-170. doi: 10.1111/apm.12789. Epub 2017 Dec 13.
28 HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. Lab Invest. 2011 Jan;91(1):124-37. doi: 10.1038/labinvest.2010.136. Epub 2010 Jul 26.
29 Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol.Carcinogenesis. 2002 Sep;23(9):1531-6. doi: 10.1093/carcin/23.9.1531.
30 Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC.BMC Cancer. 2008 May 23;8:144. doi: 10.1186/1471-2407-8-144.
31 A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma.Br J Cancer. 2000 May;82(9):1557-60. doi: 10.1054/bjoc.1999.1178.
32 Tie-1 tyrosine kinase expression in human thyroid neoplasms.Histopathology. 2004 Apr;44(4):318-22. doi: 10.1111/j.1365-2559.2003.01805.x.
33 Methylation silencing of angiopoietin-like 4 in rat and human mammary carcinomas.Cancer Sci. 2011 Jul;102(7):1337-43. doi: 10.1111/j.1349-7006.2011.01955.x. Epub 2011 May 12.
34 Proliferation and apoptosis in PhIP-induced rat mammary gland carcinomas with elevated phosphotyrosine-STAT5a.FEBS Lett. 2007 Jan 9;581(1):29-33. doi: 10.1016/j.febslet.2006.11.071. Epub 2006 Dec 5.
35 DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer.Eur J Cancer. 2011 Aug;47(12):1817-25. doi: 10.1016/j.ejca.2011.02.024. Epub 2011 Mar 31.
36 Structural insights into the inhibited states of the Mer receptor tyrosine kinase.J Struct Biol. 2009 Feb;165(2):88-96. doi: 10.1016/j.jsb.2008.10.003. Epub 2008 Nov 5.
37 Occupational trichloroethylene exposure and renal carcinoma risk: evidence of genetic susceptibility by reductive metabolism gene variants.Cancer Res. 2010 Aug 15;70(16):6527-36. doi: 10.1158/0008-5472.CAN-09-4167. Epub 2010 Jul 27.
38 Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.BMC Cancer. 2008 Jan 22;8:17. doi: 10.1186/1471-2407-8-17.
39 Loss of Cirbp expression is correlated with the malignant progression and poor prognosis in nasopharyngeal carcinoma.Cancer Manag Res. 2019 Jul 24;11:6959-6969. doi: 10.2147/CMAR.S211389. eCollection 2019.
40 Oxytocin and oxytocin-analogue F314 inhibit cell proliferation and tumor growth of rat and mouse mammary carcinomas.Int J Cancer. 1996 Jun 11;66(6):817-20. doi: 10.1002/(SICI)1097-0215(19960611)66:6<817::AID-IJC18>3.0.CO;2-#.
41 Lymphoepithelial Carcinoma of the Nasolacrimal Duct: Clinical, Radiologic, and Immunopathologic Features.Ophthalmic Plast Reconstr Surg. 2017 May/Jun;33(3S Suppl 1):S18-S21. doi: 10.1097/IOP.0000000000000478.
42 Id4 regulates mammary epithelial cell growth and differentiation and is overexpressed in rat mammary gland carcinomas.Am J Pathol. 2003 Dec;163(6):2495-502. doi: 10.1016/S0002-9440(10)63604-8.
43 CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model.Oncogene. 2013 May 30;32(22):2726-38. doi: 10.1038/onc.2012.301. Epub 2012 Jul 16.
44 Undifferentiated Endometrial Carcinomas Show Frequent Loss of Core Switch/Sucrose Nonfermentable Complex Proteins.Am J Surg Pathol. 2018 Jan;42(1):76-83. doi: 10.1097/PAS.0000000000000941.
45 Expression of nuclear membrane proteins in normal, hyperplastic, and neoplastic thyroid epithelial cells.Virchows Arch. 2015 Oct;467(4):427-36. doi: 10.1007/s00428-015-1816-6. Epub 2015 Aug 9.
46 Expression of Autophagy-Related Proteins in Different Types of Thyroid Cancer.Int J Mol Sci. 2017 Mar 2;18(3):540. doi: 10.3390/ijms18030540.
47 Vitamin D less-calcemic analog modulates the expression of estrogen receptors, vitamin D receptor and 1-hydroxylase 25-hydroxy vitamin D in human thyroid cancer cell lines.J Steroid Biochem Mol Biol. 2013 Jul;136:80-2. doi: 10.1016/j.jsbmb.2012.09.015. Epub 2012 Oct 8.
48 NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract.Am J Surg Pathol. 2008 Jun;32(6):828-34. doi: 10.1097/PAS.0b013e31815a3900.
49 Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma.Am J Surg Pathol. 2014 May;38(5):660-5. doi: 10.1097/PAS.0000000000000166.
50 Schimke Immunoosseous Dysplasia associated with undifferentiated carcinoma and a novel SMARCAL1 mutation in a child.Pediatr Blood Cancer. 2013 Sep;60(9):E88-90. doi: 10.1002/pbc.24542. Epub 2013 Apr 29.
51 Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.Gynecol Oncol. 2006 Feb;100(2):264-70. doi: 10.1016/j.ygyno.2005.08.026. Epub 2005 Oct 19.
52 Loss of heterozygosity on the short arm of chromosome 9 without p16 gene mutation in gastric carcinomas.Jpn J Cancer Res. 1995 Apr;86(4):333-5. doi: 10.1111/j.1349-7006.1995.tb03060.x.
53 High level of tumour protein p53-induced nuclear protein 1 (TP53INP1) expression in anaplastic carcinoma of the thyroid.Pathology. 2006 Dec;38(6):545-7. doi: 10.1080/00313020601024094.
54 Expression and localization of the homeodomain-containing protein HEX in human thyroid tumors.J Clin Endocrinol Metab. 2002 Mar;87(3):1376-83. doi: 10.1210/jcem.87.3.8344.
55 Epstein-Barr virus latent membrane protein-1 (LMP-1) 30-bp deletion and Xho I-loss is associated with type III nasopharyngeal carcinoma in Malaysia.World J Surg Oncol. 2008 Feb 15;6:18. doi: 10.1186/1477-7819-6-18.